EichorEICHOR
Location: Fort Wayne Synced from ClinicalTrials.gov · August 07, 2026

Clinical studies recruiting near Fort Wayne

Studies with at least one listed site matching this location on the public registry. Each page explains the study in plain language, with locations and study-team contacts. Clinicians: generate a printable list for your patient →

MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Wi
Phase 2 · National Cancer Institute (NCI) · NCT05564390A Study of IDE849 in Patients With DLL3 Expressing Tumors Including Small Cell Lung Cancer
Phase 1/Phase 2 · Fort Wayne Medical Oncology and Hematology, Inc. - Fort Wayn · IDEAYA Biosciences · NCT07174583Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-Small C
Phase 3 · NRG Oncology · NCT05624996Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease
Phase 2/Phase 3 · Parkview Regional Medical Center · NRG Oncology · NCT05174169Comparing Impact of Treatment Before or After Surgery in Patients With Stage II-IIIB Resectable Non-small Cell Lung Canc
Phase 3 · Alliance for Clinical Trials in Oncology · NCT06632327A Phase 1 of CTX-8371 in Patients With Advanced Malignancies
Phase 1 · Fort Wayne Medical Oncology and Hematology · Compass Therapeutics · NCT06150664This Study is a Non-interventional Disease Registry of Adolescent and Adult Patients With Atopic Dermatitis Who Initiate
Phase N/A · Sanofi · NCT07290803Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SL
Phase 3 · National Cancer Institute (NCI) · NCT04269902BGB-43395 Plus Letrozole Versus CDK4/6i Plus Letrozole for Patients With Advanced or Metastatic HR+/HER2- Breast Cancer
Phase 3 · Fort Wayne Medical Oncology and Hematology · BeOne Medicines · NCT07492641Docetaxel to Androgen Receptor Pathway Inhibitors in Patients With Metastatic Castration Sensitive Prostate Cancer and S
Phase 3 · Canadian Cancer Trials Group · NCT06592924Study to Learn More About the Safety and Effectiveness of the Drug VITRAKVI During Routine Use in Patients With TRK Fusi
Phase N/A · Fort Wayne Medical Oncology Hematology · Bayer · NCT04142437Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NI
Phase 1 · National Cancer Institute (NCI) · NCT03816345A Study to Evaluate the Optimal Dose, Adverse Events and Change in Disease Activity of Intravenous ABBV-706 in Combinati
Phase 2 · Fort Wayne Medical Oncology And Hematology /ID# 277336 · AbbVie · NCT07155174Collection of Research Data and Samples From Patients Who Experience Immunotherapy Side Effects
Phase N/A · Alliance for Clinical Trials in Oncology · NCT04242095Testing the Addition of Herceptin Hylecta or Phesgo to the Usual Chemotherapy for HER2 Positive Endometrial Serous Carci
Phase 3 · National Cancer Institute (NCI) · NCT05256225A Study of Nemtabrutinib Plus Venetoclax vs Venetoclax + Rituximab (VR) in Second-line (2L) + Relapsed/Refractory (R/R)
Phase 3 · Fort Wayne Medical Oncology and Hematology ( Site 5444) · Merck Sharp & Dohme LLC · NCT05947851Impact of Sentinel Lymph Node Mapping on Patient Reported Lower Extremity Limb Dysfunction in Stage I Endometrial Cancer
Phase 3 · NRG Oncology · NCT05646316A Study of Sigvotatug Vedotin in Advanced Solid Tumors
Phase 1 · Fort Wayne Medical Oncology and Hematology, Inc · Seagen, a wholly owned subsidiary of Pfizer · NCT04389632Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial
Phase 3 · ECOG-ACRIN Cancer Research Group · NCT04566328De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Eq
Phase 3 · NRG Oncology · NCT04852887mFOLFIRINOX Versus mFOLFOX With or Without Nivolumab for the Treatment of Advanced, Unresectable, or Metastatic HER2 Neg
Phase 3 · Alliance for Clinical Trials in Oncology · NCT05677490Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With
Phase 3 · National Cancer Institute (NCI) · NCT07198074Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide,
Phase 3 · National Cancer Institute (NCI) · NCT06058377A Study to Compare the Administration of Encorafenib + Binimetinib + Nivolumab Versus Ipilimumab + Nivolumab in BRAF-V60
Phase 2 · SWOG Cancer Research Network · NCT04511013Five or Ten Year Colonoscopy for 1-2 Non-Advanced Adenomatous Polyps
NA · NRG Oncology · NCT05080673TEMPUS ARIES: A Biobank Registry Platform Study in Oncology
Phase N/A · Fort Wayne · Tempus AI · NCT06207032Testing the Role of DNA Released From Tumor Cells Into the Blood in Guiding the Use of Immunotherapy After Surgical Remo
Phase 2/Phase 3 · National Cancer Institute (NCI) · NCT05987241Ramucirumab and Paclitaxel or FOLFIRI in Advanced Small Bowel Cancers
Phase 2 · SWOG Cancer Research Network · NCT04205968Patient Specific Talus Spacer Post Approval Study
Phase N/A · Fort Wayne Orthopedics · Paragon 28 · NCT05364606A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab
Phase 3 · National Cancer Institute (NCI) · NCT05675410
Look up another city
Look up another condition
Eichor
Clinical intelligence from public evidence
Use of Eichor is governed by our Terms of Use · Privacy Policy
© 2026 Biomedistats LLC (dba Eichor)

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.